| A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) (NCT05320146) | Corcept Therapeutics | 2022-03-04 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) (NCT05117489) | Corcept Therapeutics | 2021-11-23 |
| Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) (NCT04267393) | Bristol-Myers Squibb | 2021-03-17 |
| A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) (NCT04616014) | Oramed, Ltd. | 2021-03-01 |
| Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis (NCT04521114) | CytoDyn, Inc. | 2020-12-01 |
| Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) (NCT03823703) | Corcept Therapeutics | 2020-11-04 |
| Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects (NCT04546984) | Sunshine Lake Pharma Co., Ltd. | 2020-09-14 |
| Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients (NCT04977661) | Kafrelsheikh University | 2020-02-01 |
| The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects (NCT04194242) | Sunshine Lake Pharma Co., Ltd. | 2020-01-03 |
| Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER (NCT04165343) | University of California, Davis | 2019-11-01 |
| Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis (NCT03572465) | Centre hospitalier de l'Université de Montréal (CHUM) | 2019-10-23 |
| A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) (NCT04104321) | Galmed Research and Development, Ltd. | 2019-09-23 |
| The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NCT04134091) | Lipocine Inc. | 2019-08-27 |
| A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis (NCT04004325) | Forma Therapeutics, Inc. | 2019-05-17 |
| Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects (NCT06037577) | ChemomAb Ltd. | 2019-03-05 |
| Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics (NCT03392779) | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | 2018-01-05 |
| Feasibility of VIIT in Adults With NASH (NCT03861819) | Duke University | 2018-01-01 |
| Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) (NCT02854605) | Gilead Sciences | 2016-10-26 |
| Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function (NCT02891408) | Gilead Sciences | 2016-09-23 |
| Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis (NCT02856555) | Gilead Sciences | 2016-08-08 |
| Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function (NCT02808312) | Gilead Sciences | 2016-07-13 |
| Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) (NCT02781584) | Gilead Sciences | 2016-06-13 |
| Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics (NCT02654002) | Gilead Sciences | 2016-01-20 |
| Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (NCT02443116) | NGM Biopharmaceuticals, Inc | 2015-07-31 |
| Tesamorelin Effects on Liver Fat and Histology in HIV (NCT02196831) | Massachusetts General Hospital | 2015-07-01 |
| The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) (NCT01265498) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2011-03-01 |
| Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH) (NCT00845845) | University of Illinois at Chicago | 2006-03-01 |